Compare Sanofi SA (SNY) vs Western Union Co (WU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Western Union Co — how do they compare? Sanofi SA trades at $43.14 (market cap $104.06B), while Western Union Co trades at $6.95 (market cap $2.18B). The key difference: Sanofi SA is far larger — about 47.7× Western Union Co's market cap, and Western Union Co pays the higher dividend (13.43%). Which is the better fit depends on your goals.
| SNY | WU | |
|---|---|---|
Market Cap | $104.06B | $2.18B |
Sector | Health | Technology |
52-Week High | $52.34 | $10.28 |
52-Week Low | $41.33 | $6.36 |
Enterprise Value | $124.09B | $2.09B |
Dividend Yield | 5.61% | 13.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sanofi (SNY) trades at $43.155, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported strong Q2 2026 earnings, beating expectations with EPS of $1.21 versus $1.10 expected, and raised full-year guidance. Recent FDA approvals for COVID vaccines and EU approval for MenQuadfi in infants provide positive catalysts, though pipeline setbacks with an eczema drug withdrawal create uncertainty.
SNY presents a mixed outlook with solid fundamentals including a 5.4% dividend yield and reasonable valuation (P/E 22.94), but faces execution risks under new CEO leadership. Analyst consensus leans Hold (51.86%) with price target of $49.50, suggesting moderate upside potential. Key risks include drug pipeline challenges and competitive pressures in the pharmaceutical sector.
Western Union (WU) trades at $7.00, down 2.51% on the day, reflecting a bearish technical trend and mixed earnings performance with recent quarterly misses. Valuation metrics appear attractive with a P/E of 5.65 and P/S of 0.55, but revenue has declined from $4.5B in 2022 to $4.05B in 2025. The company is pursuing a $200 million cost-saving plan by 2027 and expanding its retail footprint through partnerships like Total Wireless, while its pending acquisition of Intermex faces regulatory scrutiny.
The outlook is cautious due to declining revenue, integration risks from the Intermex deal, and a high dividend yield that some analysts view as unsustainable. Near-term catalysts include regulatory approvals for the acquisition and execution of cost-cutting initiatives, but competitive pressures and margin compression pose significant risks to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Western Union Co
Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →
